Aclara Biosciences Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in the early 2000s, the company has established itself as a leader in genomic analysis and molecular diagnostics, focusing on innovative solutions for life sciences research and clinical applications. Aclara's core offerings include advanced microfluidic technologies and high-throughput screening systems, which are designed to enhance the efficiency and accuracy of genomic studies. These unique products enable researchers to conduct complex analyses with greater precision, setting Aclara apart in a competitive market. With a strong presence in North America and expanding operations globally, Aclara Biosciences has achieved significant milestones, including collaborations with leading research institutions. The company continues to solidify its market position through cutting-edge innovations and a commitment to advancing scientific discovery.
How does Aclara Biosciences Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Machinery and Equipment industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aclara Biosciences Inc.'s score of 59 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aclara Biosciences Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is part of a corporate family that includes Labcorp Holdings Inc., from which it inherits emissions data and climate commitments. As of now, Aclara has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of detailed emissions data suggests that Aclara may still be in the early stages of formalising its climate strategy. Given its relationship with Labcorp Holdings Inc., any future emissions data or climate commitments may be influenced by Labcorp's sustainability initiatives and performance metrics. As the industry increasingly prioritises carbon neutrality and sustainability, Aclara's future commitments will likely align with broader corporate trends and expectations.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 69,115,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 178,899,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
Aclara Biosciences Inc.'s Scope 3 emissions, which decreased by 4% last year and increased by approximately 10% since 2020, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 76% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aclara Biosciences Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.